A broad-spectrum novel coronavirus antigenic epitope peptide combination and its application
By screening broad-spectrum antigenic epitope peptides RBD323-337, RBD339-353, and RBD447-461, a novel coronavirus vaccine was designed, which solved the problem of decreased vaccine efficacy and achieved effective immune protection in different populations.
Patent Information
- Application Number
- CN202611519286.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-29
- Publication Date
- 2026-11-17
AI Technical Summary
Existing COVID-19 vaccines have reduced protective efficacy due to mutations targeting the spike protein (S protein) region of the virus, making them difficult to effectively prevent and treat COVID-19 infection in different populations.
Multiple broad-spectrum antigenic epitope peptides, including RBD323-337, RBD339-353, and RBD447-461, were screened out. By calculating the total population coverage frequency corresponding to their specific affinity levels, a broad-spectrum novel coronavirus vaccine was designed to induce a broad-spectrum neutralizing antibody response in the host.
This combination of antigenic epitope peptides exhibits excellent broad-spectrum antigen presentation, inducing strong CD4+ T cell responses in individuals with different HLA subtypes, providing more durable and broader-coverage immune protection.
Smart Images

Figure CN123106850A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a combination of antigenic epitope peptides of a broad-spectrum novel coronavirus and its applications. Background Technology
[0002] The novel coronavirus (SARS-CoV-2) belongs to the genus *Betacoronavirus*, is a linear single-stranded RNA (ssRNA) virus, and its genome is approximately 29,903 nucleotides long, containing 10 genes. Since the first SARS-CoV-2 genome sequence was published on January 10, 2020, several other genome sequences of the novel coronavirus isolated from patients have been released. High-throughput analysis has revealed the protein epitope profile of the entire SARS-CoV-2 genome. Related studies have found that key mutations in the spike protein RBD region significantly reduce the effectiveness of vaccines and neutralizing antibodies targeting this region, and exhibit weak cross-neutralizing activity, which limits their ability to prevent and treat highly pathogenic novel coronavirus infections.
[0003] Given the continuous mutation of SARS-CoV-2, developing safer and more effective vaccines has become a critical and urgent issue. This requires overcoming existing technological limitations and exploring novel vaccine design strategies. Currently, mainstream vaccines primarily target the viral spike protein (S protein) to induce neutralizing antibodies. However, the SARS-CoV-2 S protein, especially its receptor-binding domain (RBD), is the most frequently mutated region. Variant strains such as Omicron can evade antibody recognition through numerous mutations, leading to a significant decrease in vaccine efficacy. The human leukocyte antigen (HLA) system exhibits extremely high genetic diversity, and different populations have varying abilities to present the same epitope. Screening for broad-spectrum epitope combinations that match multiple HLA subtypes could enable vaccines to be effective in a wider range of populations.
[0004] Based on this, the present invention screened and obtained multiple broad-spectrum antigenic epitope peptides to overcome immune escape caused by viral mutations and provide more durable and broader-coverage immune protection. Summary of the Invention
[0005] One objective of this invention is to provide a broad-spectrum novel coronavirus antigenic epitope peptide combination, comprising a first antigenic epitope peptide, a second antigenic epitope peptide, and a third antigenic epitope peptide. The amino acid sequence of the first antigenic epitope peptide is shown in SEQ ID NO.1, the amino acid sequence of the second antigenic epitope peptide is shown in SEQ ID NO.2, and the amino acid sequence of the third antigenic epitope peptide is shown in SEQ ID NO.3.
[0006] In some specific embodiments, the antigen epitope peptide combination of the present invention further includes one of the following combinations: (i) A sequence having one or more amino acid substitutions, deletions, or additions compared to the sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; Or (ii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the sequence shown in SEQ ID NO.1, SEQ ID NO.2, or SEQ ID NO.3.
[0007] Furthermore, the first, second, and third antigenic epitope peptides are located in the RBD region of the S protein of the novel coronavirus.
[0008] A second objective of this invention is to provide a nucleotide sequence encoding the antigen epitope peptide combination described in the above-described scheme.
[0009] A third objective of this invention is to provide the application of the above-mentioned antigenic epitope peptide combination or the above-mentioned nucleotide sequence in the preparation of a drug for preventing novel coronavirus infection.
[0010] The fourth objective of this invention is to provide the application of the above-mentioned antigenic epitope peptide combination or the above-mentioned nucleotide sequence in the preparation of a broad-spectrum novel coronavirus vaccine.
[0011] The fifth objective of this invention is to provide a broad-spectrum novel coronavirus vaccine, which comprises the above-mentioned antigenic epitope peptide combination and an adjuvant.
[0012] This invention provides an antigenic epitope peptide combination for a broad-spectrum novel coronavirus vaccine, the antigenic epitope peptide combination comprising RBD. 323-337 RBD 339-353 and RBD 447-461 The antigen epitope peptide combination described in this invention is obtained by screening the total coverage frequency of the population corresponding to its specific affinity level, and can induce the host to produce a broad-spectrum neutralizing antibody response, which can be used to prepare a broad-spectrum novel coronavirus vaccine.
[0013] Experimental verification has shown that this combination of antigenic epitope peptides possesses excellent broad-spectrum antigen presentation properties and is capable of becoming a broad-spectrum CD4 antigen-presenting peptide. + The potential of T-cell epitope candidates provides research directions for the design of vaccines and detection kits targeting this peptide, and has important clinical significance, broad market prospects and good economic and social benefits. Attached Figure Description
[0014] Figure 1 This indicates the position of the antigen epitope peptide combination.
[0015] Figure 2 and Figure 3 The results of animal immune assessment of the antigen epitope peptide combination. Detailed Implementation
[0016] To make the technical means, creative features, achieved objectives, and effects of this invention readily understandable, the technical solutions in the embodiments of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are merely some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.
[0017] When used in conjunction with the term “comprising” in the claims and / or specification, the words “a” or “an” may mean “one”, but may also mean “one or more”, “at least one”, and “one or more”.
[0018] As used in the claims and specification, the terms “comprising,” “having,” “including,” or “containing” mean included or open-ended and do not exclude additional, uncited elements or method steps.
[0019] Throughout the application, the term “about” means: a value includes the standard deviation of the error of the apparatus or method used to determine that value.
[0020] While the disclosure supports the definition of the term "or" as merely a substitute and "and / or", the term "or" in the claims means "and / or" unless expressly stated as merely a substitute or as mutually exclusive among substitutes.
[0021] When used in claims or description, the optional / preferred "numerical range" includes both the numerical endpoints at both ends of the range and all natural numbers covered in the middle of the numerical endpoints relative to the aforementioned numerical endpoints.
[0022] As used in this disclosure, the term "amino acid mutation" includes "substitution, duplication, deletion, or addition of one or more amino acids." In this disclosure, the term "mutation" refers to a change in the amino acid sequence. In one specific embodiment, the term "mutation" refers to "substitution."
[0023] In one embodiment, the "mutation" in this disclosure may be selected from "conservative mutation". In this disclosure, the term "conservative mutation" refers to a mutation that maintains the normal function of a protein. A representative example of a conservative mutation is a conserved substitution.
[0024] The method for calculating the total population frequency covered by the same peptide segment is problematic because the MHC II (HLA-DR) gene is highly polymorphic, and the binding affinity of the same peptide segment to different alleles varies. To assess the broad-spectrum protective potential of a particular peptide segment in the population, this invention screens high-affinity peptide segments (i.e., immune-dominant epitopes) of the target antigen SARS-CoV-2 RBD by calculating the total population coverage frequency corresponding to a specific affinity level of the peptide segment. 323-337 RBD 339-353 RBD 447-461 The specific sequence is as follows: RBD 323-337 :TESIVRFPNITNLCP (SEQ ID NO.1) RBD 339-353 :GEVFNATRFASVYAW (SEQ ID NO.2) RBD 447-461 :GNYNYLYRLFRKSNL (SEQ ID NO. 3).
[0025] Subsequently, the immunogenicity of the antigenic peptides was studied using this combination of antigenic epitopes. The results showed that the combination of antigenic epitopes could stimulate cells to produce a specific T cell response.
[0026] In one technical solution of the present invention, an antigenic epitope peptide combination is provided, comprising a first antigenic epitope peptide, a second antigenic epitope peptide and a third antigenic epitope peptide. The amino acid sequence of the first antigenic epitope peptide is shown in SEQ ID NO.1, the amino acid sequence of the second antigenic epitope peptide is shown in SEQ ID NO.2, and the amino acid sequence of the third antigenic epitope peptide is shown in SEQ ID NO.3.
[0027] In some specific embodiments, the antigen epitope peptide combination of the present invention further includes one of the following combinations: (i) A sequence having one or more amino acid substitutions, deletions, or additions compared to the sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; Or (ii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the sequence shown in SEQ ID NO.1, SEQ ID NO.2, or SEQ ID NO.3.
[0028] Further structural analysis revealed that the peptide is located in the RBD region of the novel coronavirus S protein and is highly conserved.
[0029] Without substantially affecting the activity of the antigenic epitope peptide (retaining at least 95% activity), those skilled in the art can substitute, add, and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) amino acids to obtain variants of the peptide fragment sequence. These are all considered to be included within the scope of protection of this invention. For example, amino acids with similar properties can be substituted in the variable region. The variant sequences of this invention can have at least 80% identity (or homology) with the reference sequence. Sequence identity described in this invention can be measured using sequence analysis software, such as the computer program BLAST using default parameters, especially BLASTP or TBLASTN. The amino acid sequences described in this invention are shown from the N-terminus to the C-terminus.
[0030] As used in this invention, the term "sequence identity" or "percentage of identity" in the comparison of two nucleic acids or peptides refers to the percentage of identical sequences or identical sequences when compared and aligned with the highest possible correspondence using nucleotide or amino acid residue sequence comparison algorithms or by visual inspection. In other words, the identity of a nucleotide or amino acid sequence can be defined using a ratio that represents the proportion of the number of identical nucleotides or amino acids in the total number of nucleotides or amino acids in the aligned portion, assuming the maximum number of identical nucleotides or amino acids and omitting gaps as needed.
[0031] As used in this invention, sequence identity between two or more polynucleotides or polypeptides can be determined by aligning the nucleotide or amino acid sequences of the polynucleotide or polypeptide and scoring the number of positions in the aligned polynucleotide or polypeptide containing the same nucleotide or amino acid residues, comparing this to the number of positions in the aligned polynucleotide or polypeptide containing different nucleotide or amino acid residues. A polynucleotide may differ at a position, for example, by the presence or absence of a different nucleotide. A polypeptide may differ at a position, for example, by the presence or absence of a different amino acid. Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residues by the total number of amino acid residues in the polynucleotide or polypeptide. For example, the percentage of identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residues by the total number of nucleotide or amino acid residues in the polynucleotide or polypeptide and multiplying by 100.
[0032] Exemplary, in this invention, when comparing and aligning two or more sequences or subsequences using sequence comparison algorithms or by visual inspection to measure maximum correspondence, the sequences possess at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of nucleotide or amino acid residues of “sequence identity” or “identity percentage.” The determination / calculation of “sequence identity” or “identity percentage” can be based on any suitable region of the sequence. For example, a region of at least about 10 residues, a region of at least about 15 residues, a region of at least about 18 residues, or a region of at least about 20 residues. In some embodiments, the sequences are substantially identical along the entire length of any one or two compared biopolymers (i.e., nucleic acids or polypeptides).
[0033] In one embodiment of the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the aforementioned antigenic epitope peptide.
[0034] The “conventional biological methods in the art” mentioned in this invention can be found in the corresponding methods described in publications such as “Current Protocols in Molecular Biology” (Wiley) and “Molecular Cloning: A Laboratory Manual” (Cold Spring Harbor Laboratory).
[0035] Example
[0036] Other objects, features, and advantages of the present invention will become apparent from the following detailed description. However, it should be understood that the detailed description and specific embodiments (although illustrating specific implementations of this disclosure) are given for illustrative purposes only, as various changes and modifications made within the spirit and scope of the invention will become apparent to those skilled in the art upon reading this detailed description.
[0037] Unless otherwise specified, all reagents and raw materials used in this invention can be purchased commercially.
[0038] Example 1
[0039] Screening of antigenic epitope peptides Method for calculating the total population coverage of the same peptide segment: Due to the high polymorphism of the MHC II (HLA-DR) gene, the binding affinity of the same peptide segment to different alleles varies. To assess the broad-spectrum protective potential of a certain peptide segment in the population, this embodiment first calculates the total population coverage frequency corresponding to a specific affinity level through the following steps: The distribution frequency of alleles in the population was obtained: The distribution frequency of different HLA-DRB1 alleles in the global population was obtained from the Allele FrequencyNet Database (AFND). The 24 most common HLA-DR alleles selected in this invention (such as DRB1*07:01, DRB1*03:01, etc.) represent the gene frequency of 83.9% of the global population and cover 97.4% of individuals who possess at least one of these alleles.
[0040] Table 1. Coverage frequency of the top 24 DRB1 alleles in global populations.
[0041] Classification of allele binding affinity levels: For a specific polypeptide, the actual binding affinity (IC50 / Ki) to 24 HLA-DR alleles was determined by EliteMHCII assay, and its performance on each allele was classified as high, medium and low affinity based on the threshold.
[0042] Aggregated Frequency: The population coverage frequencies of all alleles that the peptide can bind at the target affinity level (e.g., "high or medium affinity": Ki < 1 μM) are summed to obtain the total coverage frequency of the peptide that can be effectively presented in the entire population.
[0043] Subsequently, high-throughput affinity assays were performed using a high-throughput competitive binding assay based on enzyme-linked immunosorbent assay (ELISA).
[0044] Recombinant protein preparation: Using the mammalian suspension cell (Expi293F) system, soluble heterodimer MHC II and HLA-DM recombinant proteins with native correct conformation were efficiently expressed by the "knob-into-hole" (KIH) Fc tag technology.
[0045] Competitive binding assay (IC50 and Ki determination): The candidate peptide to be detected, namely the SARS-CoV-2 RBD peptide (serially diluted from 10 μM to 0.6 nM), 50 nM MHC II protein, 50 nM HLA-DM catalytic protein, and 25 nM Bio-CLIP probe were mixed and incubated overnight at 37°C. HLA-DM acts as a "peptide editing enzyme" in this process, catalyzing and accelerating the dissociation of Bio-CLIP and the exchange loading of the target candidate peptide.
[0046] ELISA capture and colorimetric reading: The incubated complex was transferred to a 384-well plate pre-coated with L243 monoclonal antibody (which specifically recognizes the HLA-DR conformation) to capture the peptide-loaded MHC II molecules. After washing, streptavidin-HRP and TMB chromogenic substrate were added, and the absorbance (OD450) was measured at 450 nm after acid termination.
[0047] Affinity classification: The IC50 value of competitive binding is calculated using nonlinear regression, and the absolute affinity constant Ki value is obtained by converting it using the Cheng-Prusoff formula. This invention defines Ki < 100 nM as high affinity, 100 nM-1 μM as medium affinity, and 1 μM-10 μM as low affinity.
[0048] Table 2
[0049] The final screening identified highly conserved antigenic epitope peptides comprising the following three amino acid sequences: RBD 323-337 :TESIVRFPNITNLCP RBD 339-353 :GEVFNATRFASVYAW RBD 447-461 :GNYNYLYRLFRKSNL.
[0050] To further analyze the RBD peptides screened above... 323-337 RBD 339-353 RBD 447-461 The location information was obtained by analyzing the three-dimensional structure of the S protein and RBD domain and visualizing the peptide structure using PyMOL software, ultimately determining the location of the peptide RBD. 323-337 RBD 339-353 RBD 447-461 The specific locations of the peptides in the S protein and RBD domains are shown in the results. Figure 1 .
[0051] Example 2
[0052] Animal Immunization To further investigate whether the high-affinity peptides screened in Example 1 can induce stronger specific CD4+ + T-cell immune response was validated in vivo using a humanized mouse model of the immune system in this embodiment.
[0053] This humanized mouse model of the immune system used severely immunodeficient NCG mice (NOD PrkdcsicdIL2Rγ c- / -) as transplant recipients. Mice were subjected to sublethal irradiation within one week of birth and intrahepatic injection of human CD34 purified from human fetal liver. + Hematopoietic stem and progenitor cells (HSPCs). The selected HSPCs carried HLA-DRB1*01:01 and HLA-DRB1*14:54 haplotypes from specific donors, thereby reconstructing a humanized immune system in vivo.
[0054] A multi-stage immunization strategy is adopted. Details are as follows: Initial immunization (Day 0): Mice were divided into a high-affinity group and a control group. The high-affinity group received an intraperitoneal injection (ip) of a high-affinity peptide fragment (RBD). 323-337 RBD 339-353 RBD 447-461 The mixture consisted of 100 μg of each peptide, totaling 300 μg, and was mixed with 20 μg of CpG adjuvant for immunization. The control group received intraperitoneal injection (ip) of the non-immunogenic peptide GS linkerpeptide (GSGSGSGSGSGS).
[0055] Antigen-activated B cell response (Day 7): Mice were injected intraperitoneally with 20 μg of recombinant RBD-Fc protein and 100 μL of aluminum adjuvant to mimic antigen presentation and induce a high level of antibody response.
[0056] Booster vaccination (Day 14): A booster immunization was performed using the same peptide pool formulation as Day 0, with the addition of CpG adjuvant.
[0057] Sampling and endpoint detection (Day 20): On day 20 after the first vaccination (i.e., 6 days after the booster immunization), mice were sacrificed and spleens were collected.
[0058] Preparation of spleen single-cell suspension: Mouse spleens were removed, mechanically ground, filtered through a 70 μm sieve, and erythrocytes were lysed using ACK lysis buffer. Peptide-specific CD4 + T cell quantification (tetramer staining): Spleen cells were incubated with fluorescently labeled HLA-DRB1*01:01 and HLA-DRB1*14:54 MHC II tetramers specifically loaded with corresponding peptides. Human CD4 counts specific to high / low affinity peptides were detected and calculated by flow cytometry (FACS). +T cell frequency. In vitro restimulation and activation marker detection (AIM): Splenocytes were stimulated in vitro with the corresponding peptide at 50 μg / mL for 2 hours, and then co-incubated at 37°C for 4 hours in the presence of Brefeldin A. Subsequently, the activation-inducing marker CD69 was analyzed in human CD4+ using surface marker staining. + The expression status on the surface of T cells was used to assess the functional activation status of T cells after antigen stimulation.
[0059] like Figure 2 and Figure 3 As shown, compared with the control group, mice in the high-affinity peptide group showed increased specific CD4 counts against the high-affinity peptide. + The frequency of T cells increased significantly.
Claims
1. A combination of antigenic epitope peptides, characterized in that, Including the first antigenic epitope peptide, the second antigenic epitope peptide, and the third antigenic epitope peptide; The first, second, and third antigenic epitope peptides are selected from one of the following: (i) The amino acid sequence of the first antigenic epitope peptide is shown in SEQ ID NO.1, the amino acid sequence of the second antigenic epitope peptide is shown in SEQ ID NO.2, and the amino acid sequence of the third antigenic epitope peptide is shown in SEQ ID NO.3; (ii) A sequence having one or more amino acid substitutions, deletions, or additions compared to the sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; Or (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the sequence shown in SEQ ID NO.1, SEQ ID NO.2, or SEQ ID NO.
3.
2. The antigen epitope peptide combination according to claim 1, characterized in that, The first, second, and third antigenic epitope peptides are located in the RBD region of the S protein of the novel coronavirus.
3. The nucleotide sequence encoding the antigenic epitope peptide combination of claim 1.
4. The use of the antigenic epitope peptide combination of claim 1 or the nucleotide sequence of claim 3 in the preparation of a medicament for preventing novel coronavirus infection.
5. The use of the antigenic epitope peptide combination of claim 1 or the nucleotide sequence of claim 3 in the preparation of a broad-spectrum novel coronavirus vaccine.
6. A broad spectrum novel coronavirus vaccine, characterized in that, The broad-spectrum novel coronavirus vaccine comprises the antigenic epitope peptide combination and adjuvant as described in claim 1.
